Soria, J-C <br/><br/>
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Nov 2014 
 - 2244-2251 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdu390  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug-Related Side Effects and Adverse Reactions--pathology<br/>Female<br/>Humans<br/>Middle Aged<br/>Naphthalenes--analysis<br/>Neoplasms--classification<br/>Neovascularization, Pathologic--drug therapy<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinolines--analysis<br/>Receptor, Fibroblast Growth Factor, Type 1--antagonists & inhibitors<br/>Receptor, Fibroblast Growth Factor, Type 2--antagonists & inhibitors<br/>Receptors, Platelet-Derived Growth Factor<br/>Vascular Endothelial Growth Factor Receptor-1--antagonists & inhibitors